Adaptive Biotechnologies Announces Business Update Conference Call and Webcast Set for April 2, 2024

Unlocking the Secrets of the Adaptive Immune System: How Adaptive Biotechnologies Corporation is Leading the Charge in Personalized Immunotherapy

Seattle-based biotechnology company Adaptive Biotechnologies Corporation, listed on Nasdaq as ADPT, is focused on translating the genetics of the adaptive immune system into clinical products for diagnosing and treating diseases. The company’s Vice President of Investor Relations, Karina Calzadilla, can be reached at 201-396-1687 or for inquiries from investors.

The adaptive immune system holds great potential for diagnosing and treating diseases, but its complexity has limited its full utilization. Adaptive Biotechnologies aims to decode and leverage the genetics of the adaptive immune system with scale, precision, and speed through their immune medicine platform. They collaborate with biopharmaceutical companies, inform drug development, and develop clinical diagnostics in two main areas: Minimal Residual Disease (MRD) and Immune Medicine. Their products and clinical pipeline focus on diagnosing, monitoring, and treating diseases like cancer, autoimmune disorders, and infectious diseases with the goal of creating personalized immune-driven clinical products for each patient.

On April 2nd, 2024 after the market closes, Adaptive Biotechnologies will host a business update conference call and webcast accessible through their website at in the “Investors” section. The webcast will also be archived for replay within 24 hours. For media inquiries related to this event or other topics related to Adaptive Biotechnologies Corporation please contact Erica Jones at 206-279-2423 or

Leave a Reply

China to oppose Biden’s electric vehicle agenda at the WTO Previous post China’s Electrifying Dispute with the US: What it Means for the Global Automotive Industry
Institute lowers forecasts as German economy faces challenges Next post Germany’s Economic Outlook: Navigating Headwinds and Challenges Ahead